Knowing how environmental pressures shape human evolution can lead to a better understanding of why certain populations or ethnic groups today are predisposed to certain characteristics.
An FDA-approved drug originally designed to treat cancer may be an unlikely potential ally in the global fight against tuberculosis, a new study suggests.
An investigational drug in clinical trials for rheumatoid arthritis also prevents a common, life-threatening side effect of stem cell transplants, new research shows.
Cancer has always been thought of as something that grows rapidly and uncontrollably, but this view may be wrong. New evidence suggests that cancer has a smarter strategy than that.
We have achieved so much since the full human genome sequence was published for the first time, can you believe that was over fifteen years ago this month?
President Donald Trump’s upcoming speech on drug prices comes after months of public comments and debate about tackling the issue.
Researchers have mapped the genetic variants that increase the risk of depression, in a bid to understand why depression strikes some people and not others.
Biomedical engineers have used a CRISPR/Cas9 genetic engineering technique to turn off a gene that regulates cholesterol levels in adult mice, leading to reduced blood cholesterol levels and gene repression lasting for six months after a single treatment.
Illumina Accelerator, the genomics-focused startup accelerator backed by the publicly traded Illumina, has revealed that it’s picked five startups for its seventh accelerator class.
Biotech startup Mammoth Biosciences launches a CRISPR powered search engine that ‘works like Google’ for disease detection.
An international consortium of researchers is organising a massive effort to collect and sequence the DNA of Earth’s 1.5 million known Eukaryotes.
It’s no secret that China has become an ever-increasing component for drug development, and their pharmaceutical market value proves just that.
After a lot of back and forth, Shire has landed on a proposal worth recommending to shareholders with Takeda. This $64 billion deal, is the biggest in pharma for years.
Scientists have published the first detailed picture of the molecular structure of human telomerase, which will allow more targeted drug screens and intelligent design of new drugs.
Doctors in Germany have for the first time, successfully treated twins in utero using a biotech drug, pointing to a new way to eliminate disease.